Life Technologies, a global biotech company based in Carlsbad, California, announced the launch of a new partnership with Boston Children’s Hospital. Both groups will work together to launch Claritas Genomics, a venture that will develop future diagnostic technologies based on genomics.
According to a press release by Life Technologies, Boston Children’s Hospital will own a majority stake in Claritas Genomics and will operate the venture out of its CLIA-certified diagnostic lab. Life Technologies will contribute its Ion Proton Sequencer for the development of molecular diagnostic tools.
For Life Technologies, this joint venture represents the latest in a string of team-ups and acquisitions over the past year. According to information from the company, the slew of recent developments is part of the company's strategy to speed up the development of companion diagnostics and assays.
Greg Lucier is the CEO of Life Technologies. In prepared remarks, he said, “"Our investment in Claritas Genomics is a prime example of strategic partnerships Life Technologies is entering into to accelerate the use of accurate genomic information in medical practice." He continued, "This new venture serves as a model for future endeavors to demonstrate the validation of our Ion Torrent technology in an integrated laboratory workflow designed for clinical applications related to pediatrics and inherited diseases."
Boston Children’s Hospital states that it will use Claritas Genomics to improve existing genomics research efforts at the facility. The group also plans to turn research into actionable diagnostic solutions in the future.